Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. (Q41811594)
Jump to navigation
Jump to search
scientific article published on 2 May 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. |
scientific article published on 2 May 2012 |
Statements
1 reference
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. (English)
1 reference
1 reference
Pasi A Jänne
1 reference
Lu Xu
1 reference
Eiki Kikuchi
1 reference
Chunxiao Xu
1 reference
Dalia Ercan
1 reference
Katherine A Cheng
1 reference
Robert Padera
1 reference
Jeffrey A Engelman
1 reference
Geoffrey I Shapiro
1 reference
Takeshi Shimamura
1 reference
Kwok-Kin Wong
1 reference
Identifiers
1 reference